^
Association details:
| Biomarker: | Chr t(14;20) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug Class: | Proteasome inhibitor + Immunomodulator |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Cytogenetic abnormalities in MM: Association with disease characteristics and treatment response.
Published date:
05/29/2020
Excerpt:
The rate of ≥ very good partial response was higher for patients with high risk IgH translocations [t(4;14), t(14;16) or t(14;20)] compared to standard risk with PI-IMiD combination treatment (88% vs 65% P < 0.01).
DOI:
10.1200/JCO.2020.38.15_suppl.e20520
